43 related articles for article (PubMed ID: 31107542)
1. Impact of single-nucleotide polymorphisms in DNA repair pathway genes on response to chemoradiotherapy in rectal cancer patients: Results from ACCORD-12/PRODIGE-2 phase III trial.
Boige V; Mollevi C; Gourgou S; Azria D; Seitz JF; Vincent M; Bigot L; Juzyna B; Miran I; Gerard JP; Laurent-Puig P
Int J Cancer; 2019 Dec; 145(11):3163-3172. PubMed ID: 31107542
[TBL] [Abstract][Full Text] [Related]
2. Prospective clinical study of capecitabine plus oxaliplatin concurrent chemoradiotherapy after radical resection of rectal cancer.
Chen W; Wang W; Li Y; Dong H; Wang G; Li X
Cancer Cell Int; 2018; 18():123. PubMed ID: 30181716
[TBL] [Abstract][Full Text] [Related]
3. A common variant in MTHFR influences response to chemoradiotherapy and recurrence of rectal cancer.
Nikas JB; Lee JT; Maring ED; Washechek-Aletto J; Felmlee-Devine D; Johnson RA; Smyrk TC; Tawadros PS; Boardman LA; Steer CJ
Am J Cancer Res; 2015; 5(10):3231-40. PubMed ID: 26693073
[TBL] [Abstract][Full Text] [Related]
4. Compliance and tolerability of short-course radiotherapy followed by preoperative chemotherapy and surgery for high-risk rectal cancer - Results of the international randomized RAPIDO-trial.
van der Valk MJM; Marijnen CAM; van Etten B; Dijkstra EA; Hilling DE; Kranenbarg EM; Putter H; Roodvoets AGH; Bahadoer RR; Fokstuen T; Ten Tije AJ; Capdevila J; Hendriks MP; Edhemovic I; Cervantes AMR; de Groot DJA; Nilsson PJ; Glimelius B; van de Velde CJH; Hospers GAP;
Radiother Oncol; 2020 Jun; 147():75-83. PubMed ID: 32240909
[TBL] [Abstract][Full Text] [Related]
5. Impact on health-related quality of life deterioration-free survival of a first-line therapy combining nab-paclitaxel plus either gemcitabine or simplified leucovorin and fluorouracil for patients with metastatic pancreatic cancer: Results of the randomized phase II AFUGEM GERCOR clinical trial.
Charton E; Bachet JB; Hammel P; Desramé J; Chibaudel B; Cohen R; Debourdeau P; Dauba J; Lecomte T; Seitz JF; Tournigand C; Aparicio T; Guerin-Meyer V; Taieb J; Volet J; Louvet C; Anota A; Bonnetain F
Cancer Med; 2019 Sep; 8(11):5079-5088. PubMed ID: 31314957
[TBL] [Abstract][Full Text] [Related]
6. Total Neoadjuvant Therapy in Rectal Cancer: A Systematic Review and Meta-analysis of Treatment Outcomes.
Petrelli F; Trevisan F; Cabiddu M; Sgroi G; Bruschieri L; Rausa E; Ghidini M; Turati L
Ann Surg; 2020 Mar; 271(3):440-448. PubMed ID: 31318794
[TBL] [Abstract][Full Text] [Related]
7. Triplet combination of durvalumab, tremelimumab, and paclitaxel in biliary tract carcinomas: Safety run-in results of the randomized IMMUNOBIL PRODIGE 57 phase II trial.
Boilève A; Hilmi M; Gougis P; Cohen R; Rousseau B; Blanc JF; Ben Abdelghani M; Castanié H; Dahan L; Tougeron D; Metges JP; Tournigand C; Garcia-Larnicol ML; Vernerey D; Turpin A; Neuzillet C
Eur J Cancer; 2021 Jan; 143():55-63. PubMed ID: 33279854
[TBL] [Abstract][Full Text] [Related]
8. RECIST and iRECIST criteria for the evaluation of nivolumab plus ipilimumab in patients with microsatellite instability-high/mismatch repair-deficient metastatic colorectal cancer: the GERCOR NIPICOL phase II study.
Cohen R; Bennouna J; Meurisse A; Tournigand C; De La Fouchardière C; Tougeron D; Borg C; Mazard T; Chibaudel B; Garcia-Larnicol ML; Svrcek M; Vernerey D; Menu Y; André T
J Immunother Cancer; 2020 Nov; 8(2):. PubMed ID: 33148693
[TBL] [Abstract][Full Text] [Related]
9. Sorafenib Plus Irinotecan Combination in Patients With RAS-mutated Metastatic Colorectal Cancer Refractory To Standard Combined Chemotherapies: A Multicenter, Randomized Phase 2 Trial (NEXIRI-2/PRODIGE 27).
Samalin E; Fouchardière C; Thézenas S; Boige V; Senellart H; Guimbaud R; Taïeb J; François E; Galais MP; Lièvre A; Seitz JF; Metges JP; Bouché O; Boissière-Michot F; Lopez-Crapez E; Bibeau F; Ho-Pun-Cheung A; Ychou M; Adenis A; Di Fiore F; Mazard T
Clin Colorectal Cancer; 2020 Dec; 19(4):301-310.e1. PubMed ID: 32737004
[TBL] [Abstract][Full Text] [Related]
10. Gemcitabine plus nab-paclitaxel until progression or alternating with FOLFIRI.3, as first-line treatment for patients with metastatic pancreatic adenocarcinoma: The Federation Francophone de Cancérologie Digestive-PRODIGE 37 randomised phase II study (FIRGEMAX).
Rinaldi Y; Pointet AL; Khemissa Akouz F; Le Malicot K; Wahiba B; Louafi S; Gratet A; Miglianico L; Laharie H; Bouhier Leporrier K; Thirot Bidault A; Texereau P; Coriat R; Terrebonne E; Gouttebel MC; Malka D; Bachet JB; Lepage C; Taieb J;
Eur J Cancer; 2020 Sep; 136():25-34. PubMed ID: 32623182
[TBL] [Abstract][Full Text] [Related]
11. Special considerations in the management of adult patients with acute leukaemias and myeloid neoplasms in the COVID-19 era: recommendations from a panel of international experts.
Zeidan AM; Boddu PC; Patnaik MM; Bewersdorf JP; Stahl M; Rampal RK; Shallis R; Steensma DP; Savona MR; Sekeres MA; Roboz GJ; DeAngelo DJ; Schuh AC; Padron E; Zeidner JF; Walter RB; Onida F; Fathi A; DeZern A; Hobbs G; Stein EM; Vyas P; Wei AH; Bowen DT; Montesinos P; Griffiths EA; Verma AK; Keyzner A; Bar-Natan M; Navada SC; Kremyanskaya M; Goldberg AD; Al-Kali A; Heaney ML; Nazha A; Salman H; Luger S; Pratz KW; Konig H; Komrokji R; Deininger M; Cirici BX; Bhatt VR; Silverman LR; Erba HP; Fenaux P; Platzbecker U; Santini V; Wang ES; Tallman MS; Stone RM; Mascarenhas J
Lancet Haematol; 2020 Aug; 7(8):e601-e612. PubMed ID: 32563283
[TBL] [Abstract][Full Text] [Related]
12. Guidelines for time-to-event end-point definitions in adjuvant randomised trials for patients with localised colon cancer: Results of the DATECAN initiative.
Cohen R; Vernerey D; Bellera C; Meurisse A; Henriques J; Paoletti X; Rousseau B; Alberts S; Aparicio T; Boukovinas I; Gill S; Goldberg RM; Grothey A; Hamaguchi T; Iveson T; Kerr R; Labianca R; Lonardi S; Meyerhardt J; Paul J; Punt CJA; Saltz L; Saunders MP; Schmoll HJ; Shah M; Sobrero A; Souglakos I; Taieb J; Takashima A; Wagner AD; Ychou M; Bonnetain F; Gourgou S; Yoshino T; Yothers G; de Gramont A; Shi Q; André T;
Eur J Cancer; 2020 May; 130():63-71. PubMed ID: 32172199
[TBL] [Abstract][Full Text] [Related]
13. [Does the FLOT regimen a new standard of perioperative chemotherapy for localized gastric cancer?].
Adenis A; Samalin E; Mazard T; Portales F; Mourregot A; Ychou M
Bull Cancer; 2020 Jan; 107(1):54-60. PubMed ID: 31980145
[TBL] [Abstract][Full Text] [Related]
14. Erythrocyte-encapsulated asparaginase (eryaspase) combined with chemotherapy in second-line treatment of advanced pancreatic cancer: An open-label, randomized Phase IIb trial.
Hammel P; Fabienne P; Mineur L; Metges JP; Andre T; De La Fouchardiere C; Louvet C; El Hajbi F; Faroux R; Guimbaud R; Tougeron D; Bouche O; Lecomte T; Rebischung C; Tournigand C; Cros J; Kay R; Hamm A; Gupta A; Bachet JB; El Hariry I
Eur J Cancer; 2020 Jan; 124():91-101. PubMed ID: 31760314
[TBL] [Abstract][Full Text] [Related]
15. Everolimus after hepatic arterial embolisation therapy of metastases from gastrointestinal neuroendocrine tumours: The FFCD 1104-EVACEL-GTE phase II study.
Walter T; Lepage C; Coriat R; Barbier E; Cadiot G; Caroli-Bosc FX; Aparicio T; Bouhier-Leporrier K; Hentic-Dhome O; Gay F; Dupont-Gossart AC; Duluc M; Lepere C; Lecomte T; Smith D; Petorin C; Di-Fiore F; Ghiringhelli F; Legoux JL; Guimbaud R; Baudin E; Lombard-Bohas C; de Baère T;
Eur J Cancer; 2019 Dec; 123():92-100. PubMed ID: 31678771
[TBL] [Abstract][Full Text] [Related]
16. [Dihydropyrimidine dehydrogenase deficiency screening for management of patients receiving a fluoropyrimidine: Results of two national practice surveys addressed to clinicians and biologists].
Loriot MA; Masskouri F; Carni P; Le Malicot K; Seitz JF; Michel P; Legoux JL; Bouché O; André T; Faroux R; Delaloge S; Malka D; Guigay J; Thariat J; Thomas F; Barin-Le-Guellec C; Ciccolini J; Boyer JC; Étienne-Grimaldi MC
Bull Cancer; 2019 Sep; 106(9):759-775. PubMed ID: 31253356
[TBL] [Abstract][Full Text] [Related]
17. Acute Myeloid Leukemia, Version 3.2019, NCCN Clinical Practice Guidelines in Oncology.
Tallman MS; Wang ES; Altman JK; Appelbaum FR; Bhatt VR; Bixby D; Coutre SE; De Lima M; Fathi AT; Fiorella M; Foran JM; Hall AC; Jacoby M; Lancet J; LeBlanc TW; Mannis G; Marcucci G; Martin MG; Mims A; O'Donnell MR; Olin R; Peker D; Perl A; Pollyea DA; Pratz K; Prebet T; Ravandi F; Shami PJ; Stone RM; Strickland SA; Wieduwilt M; Gregory KM; ; Hammond L; Ogba N
J Natl Compr Canc Netw; 2019 Jun; 17(6):721-749. PubMed ID: 31200351
[TBL] [Abstract][Full Text] [Related]
18. Immunogenomic profiles associated with response to neoadjuvant chemoradiotherapy in patients with rectal cancer.
Akiyoshi T; Tanaka N; Kiyotani K; Gotoh O; Yamamoto N; Oba K; Fukunaga Y; Ueno M; Mori S
Br J Surg; 2019 Sep; 106(10):1381-1392. PubMed ID: 31197828
[TBL] [Abstract][Full Text] [Related]
19. Neoadjuvant Chemotherapy in Locally Advanced Rectal Cancer.
Papaccio F; Roselló S; Huerta M; Gambardella V; Tarazona N; Fleitas T; Roda D; Cervantes A
Cancers (Basel); 2020 Dec; 12(12):. PubMed ID: 33287114
[TBL] [Abstract][Full Text] [Related]
20. Role of Single-Nucleotide Polymorphisms in Genes Implicated in Capecitabine Pharmacodynamics on the Effectiveness of Adjuvant Therapy in Colorectal Cancer.
Cura Y; Sánchez-Martín A; Márquez-Pete N; González-Flores E; Martínez-Martínez F; Pérez-Ramírez C; Jiménez-Morales A
Int J Mol Sci; 2023 Dec; 25(1):. PubMed ID: 38203276
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]